EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Insights into Clinical Trials for Drugs Targeting MASLD : Progress, Challenges, and Future Directions

Yu Wu iD, Pu Dong, Qifang Wu iD, Ya Zhang iD, Gang Xu, Chenwei Pan, Haibin Tong iD

Clinical Pharmacology & Therapeutics · 2025-06 · 117 (6) · 1614-1626

DOI: 10.1002/cpt.3606 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 14.02.2025. Verfasst von Yu Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Life and Environmental Science, Wenzhou University, Wenzhou, China. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Fatty Liver, Non-alcoholic Fatty Liver Disease, Metabolic Diseases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 95 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The transition in terminology from fatty liver disease to metabolic dysfunction‐associated steatotic liver disease (MASLD) marks a considerable evolution in diagnostic standards. This new definition focuses on liver fat accumulation in the context of overweight/obesity, type 2 diabetes, or metabolic dysfunction, without requiring the exclusion of other concurrent liver diseases. The new definition also provides clear guidelines for defining alcohol consumption in relation to the disease. MASLD is currently acknowledged as the most widespread liver disorder globally, affecting ~25% of the population. Despite the extensive array of clinical trials conducted in recent years, the number of approved treatments for metabolic dysfunction‐associated fatty liver disease is very limited. In the review critically evaluates the results of clinical trials of related drugs and assesses the future directions for drug development trials. The renaming of MASLD presents new challenges and opportunities for the design of clinical trials and the selection of target populations for drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicFatty LiverNon-alcoholic Fatty Liver DiseaseMetabolic DiseasesHumansDrug DevelopmentDiabetes Mellitus, Type 2Obesity

Autor:innen und Institutionen

  • College of Life and Environmental Science, Wenzhou University, Wenzhou, China.
  • Department of Infectious Diseases, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Hepatology Diagnosis and Treatment Center & Zhejiang Provincial Key Laboratory for Accurate Diagnosis and Treatment of Chronic Liver Diseases, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Department of Infectious Diseases, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.
  • Wenzhou Key Laboratory of Precision General Practice and Health Management, Wenzhou, China.

ORCID-Profile: Yu Wu, Qifang Wu, Ya Zhang, Haibin Tong

Zitieren

APA

Wu, Y., Dong, P., Wu, Q., Zhang, Y., Xu, G., Pan, C., & Tong, H. (2025). Insights into Clinical Trials for Drugs Targeting MASLD : Progress, Challenges, and Future Directions. Clinical Pharmacology & Therapeutics, 117(6), 1614-1626. https://doi.org/10.1002/cpt.3606

Vancouver

Wu Y, Dong P, Wu Q, Zhang Y, Xu G, Pan C, et al. Insights into Clinical Trials for Drugs Targeting MASLD : Progress, Challenges, and Future Directions. Clinical Pharmacology & Therapeutics. 2025;117(6):1614-1626. doi:10.1002/cpt.3606

BibTeX
@article{Wu2025,
  author = {Wu, Yu and Dong, Pu and Wu, Qifang and Zhang, Ya and Xu, Gang and Pan, Chenwei and Tong, Haibin},
  title = {Insights into Clinical Trials for Drugs Targeting MASLD : Progress, Challenges, and Future Directions},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {6},
  pages = {1614--1626},
  doi = {10.1002/cpt.3606}
}
Kostenlos starten →